Stryker sells BMP products to Mariel
This article was originally published in Scrip
Executive Summary
Stryker has offloaded its bone morphogenetic protein-7 (BMP-7) assets to pharmaceutical company Mariel Therapeutics for an undisclosed fee. Mariel plans to develop the technology for the treatment of osteoarthritis, chronic kidney disease (CKD) and other organ fibrosis conditions, lupus, and obesity. However, Stryker has not turned its back on the products completely: as part of the agreement, it will have a right of first negotiation for commercial rights in the area of osteoarthritis.